Literature DB >> 34070901

Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells.

Sofía Valla1,2, Nourhan Hassan3, Daiana Luján Vitale2,4, Daniela Madanes5, Fiorella Mercedes Spinelli2,4, Felipe C O B Teixeira3, Burkhard Greve6, Nancy Adriana Espinoza-Sánchez3,6, Carolina Cristina1,2, Laura Alaniz2,4, Martin Götte3.   

Abstract

Glycosaminoglycans (GAGs) and proteoglycans (PGs) are major components of the glycocalyx. The secreted GAG and CD44 ligand hyaluronic acid (HA), and the cell surface PG syndecan-1 (Sdc-1) modulate the expression and activity of cytokines, chemokines, growth factors, and adhesion molecules, acting as critical regulators of tumor cell behavior. Here, we studied the effect of Sdc-1 siRNA depletion and HA treatment on hallmark processes of cancer in breast cancer cell lines of different levels of aggressiveness. We analyzed HA synthesis, and parameters relevant to tumor progression, including the stem cell phenotype, Wnt signaling constituents, cell cycle progression and apoptosis, and angiogenic markers in luminal MCF-7 and triple-negative MDA-MB-231 cells. Sdc-1 knockdown enhanced HAS-2 synthesis and HA binding in MCF-7, but not in MDA-MB-231 cells. Sdc-1-depleted MDA-MB-231 cells showed a reduced CD24-/CD44+ population. Furthermore, Sdc-1 depletion was associated with survival signals in both cell lines, affecting cell cycle progression and apoptosis evasion. These changes were linked to the altered expression of KLF4, MSI2, and miR-10b and differential changes in Erk, Akt, and PTEN signaling. We conclude that Sdc-1 knockdown differentially affects HA metabolism in luminal and triple-negative breast cancer model cell lines and impacts the stem phenotype, cell survival, and angiogenic factors.

Entities:  

Keywords:  angiogenesis; apoptosis; breast cancer; hyaluronic acid; stem cells; syndecan-1

Year:  2021        PMID: 34070901     DOI: 10.3390/ijms22115874

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  57 in total

Review 1.  Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance.

Authors:  Daiana Vitale; Sampath Kumar Katakam; Burkhard Greve; Bohee Jang; Eok-Soo Oh; Laura Alaniz; Martin Götte
Journal:  FEBS J       Date:  2019-06-27       Impact factor: 5.542

2.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

3.  MDA-MB-231 breast cancer cell viability, motility and matrix adhesion are regulated by a complex interplay of heparan sulfate, chondroitin-/dermatan sulfate and hyaluronan biosynthesis.

Authors:  Manuela Viola; Kathrin Brüggemann; Evgenia Karousou; Ilaria Caon; Elena Caravà; Davide Vigetti; Burkhard Greve; Christian Stock; Giancarlo De Luca; Alberto Passi; Martin Götte
Journal:  Glycoconj J       Date:  2016-10-15       Impact factor: 2.916

4.  Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns.

Authors:  C W Kim; O A Goldberger; R L Gallo; M Bernfield
Journal:  Mol Biol Cell       Date:  1994-07       Impact factor: 4.138

5.  Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Christine Earle; Katherine Krueger; Christina C Spevak
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

6.  Expression of hyaluronan in benign and malignant breast lesions.

Authors:  P K Auvinen; J J Parkkinen; R T Johansson; U M Agren; R H Tammi; M J Eskelinen; V M Kosma
Journal:  Int J Cancer       Date:  1997-10-21       Impact factor: 7.396

Review 7.  Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.

Authors:  Martin Götte; George W Yip
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

Review 8.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

9.  High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.

Authors:  Mattia Barbareschi; Patrick Maisonneuve; Daniela Aldovini; Maria Giulia Cangi; Lorenza Pecciarini; Francesco Angelo Mauri; Silvio Veronese; Orazio Caffo; Antonio Lucenti; Paolo Dalla Palma; Enzo Galligioni; Claudio Doglioni
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

10.  MicroRNA-10b expression in node-negative breast cancer-correlation with metastasis and angiogenesis.

Authors:  Xia Liu; Yong Guan; Li Wang; Yun Niu
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

View more
  2 in total

1.  The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis.

Authors:  Lara Hillemeyer; Nancy Adriana Espinoza-Sanchez; Burkhard Greve; Nourhan Hassan; Anca Chelariu-Raicu; Ludwig Kiesel; Martin Götte
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

2.  LncRNA MBNL1-AS1 Represses Proliferation and Cancer Stem-Like Properties of Breast Cancer through MBNL1-AS1/ZFP36/CENPA Axis.

Authors:  Yu Ding; Yingjie Li; Yunqiang Duan; Wan Wang; Wei Zheng; Weilun Cheng; Yuan Qi; Jianyuan Feng; Ziang Chen; Tianshui Yu; Anbang Hu; Ting Wang; Mingcui Li; Hanyu Zhang; Yanling Li; Fei Ma; Baoliang Guo
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.